Thalassemia

Hematology

Volumn 17, Issue SUPPL. 1, 2012, Pages

  Aydinok, Yesim ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Beta thalassemia; Blood transfusion; Iron chelators; Iron overload

Indexed keywords

ALPHA GLOBULIN; BETA GLOBULIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ERYTHROPOIETIN; FERRITIN;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; AGRANULOCYTOSIS; ALLELE; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL FEATURE; CLINICAL PRACTICE; COLOR VISION DEFECT; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE CARRIER; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG MEGADOSE; ENZYME BLOOD LEVEL; FERRITIN BLOOD LEVEL; GENE THERAPY; GENETIC COUNSELING; GENETIC SCREENING; HEARING LOSS; HEART FAILURE; HEMATOLOGIC DISEASE; HIGH RISK POPULATION; HLA MATCHING; HOMEOSTASIS; HOMOZYGOSITY; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; KIDNEY DISEASE; LIVER DYSFUNCTION; MEDICAL RESEARCH; MONOTHERAPY; NAUSEA; OVERALL SURVIVAL; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERCEPTION DEAFNESS; POPULATION MIGRATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PUBLIC HEALTH PROBLEM; QUALITY OF LIFE; RASH; RETINOPATHY; SIDE EFFECT; SPLENECTOMY; STEM CELL TRANSPLANTATION; THALASSEMIA MAJOR; TREATMENT INDICATION; TREATMENT RESPONSE; TROPICS; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; VOMITING;

BETA-THALASSEMIA; BLOOD TRANSFUSION; GENE THERAPY; HUMANS; INFANT; IRON CHELATING AGENTS; IRON OVERLOAD; STEM CELL TRANSPLANTATION;

EID: 84859780597     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13336169155295     Document Type: Article

References (24)

1. Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove P. Inherited disorders of hemoglobin. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. Disease control priorities in developing countries. 2nd ed. Washington (DC): World Bank; 2006. Chapter 34; p. 663-80.
2. Cooley TB, Lee OP. Series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans Amer Pediatr Soc. 1925;37:29.
3. Rietti F. Ittero emolytica primitive. Atti Acad Scient Med Nat Ferrara. 1925;2:14-9.
4. Valentine WN, Neel JV. Hematologic and genetic study of the transmission of thalassemia. Arch Int Med. 1944;74:185.
5. Weatherall DJ, Clegg JB. Thalassemia-a global public health problem. Nat Med. 1996;2:847-9.
6. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86:480-7.
7. Weatherall DJ. Genetic variation and susceptibility to infection: the red cell and malaria. Br J Haematol. 2008;141:276-86.
8. Lo YM. Fetal nucleic acids in maternal blood: the promises. Clin Chem Lab Med. In press 2011.
9. Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. In press 2011.
10. Olivieri NF. The beta-thalassaemias. N Engl J Med. 1999;341:99-109.
11. Nemeth E. Hepsidin in beta-thalassaemia. Ann N Y Acad Sci. 2010;1202:31-5.
12. Porter JB, Shah FT. Iron overload in thalassemia and related conditions: Therapeutic goals and assessment of response to chelation therapies. Hematol Oncol Clin N Am. 2010;24:1109-30.
13. Cao A, Galanello R. Beta-thalassemia. GenetMed. 2010;12:61-76.
14. Cohen A, Gayer R, Mizanin J. Long term effect of splenectomy on transfusion requirements in thalassaemia major. Am J Hematol. 1989;30:254-6.
15. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-9.
16. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95:1229-36.
17. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17-24.
18. Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, et al. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica. 2007;92:1599-606.
19. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738-44.
20. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876-84.
21. Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2011;118:884-93.
22. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, et al. Continued improvement and normalization of myocardial T2* in patients with beta-thalassemia major treated with Deferasirox (ExjadeH) for up to 3 years. ASH 2010 Blood. 2010;116:abstract 4276.
23. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42.
24. Angelucci E. Hematopoietic stem cell transplantation in thalassemia. 2010;2010:456-62.